×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVBP – arrivent biopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVBP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
9/17
06:02 pm
avbp
ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]
Low
Report
ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]
9/11
12:19 pm
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.
9/10
12:10 pm
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.
9/10
10:04 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.
9/10
08:01 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.
9/9
12:09 pm
avbp
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer [Yahoo! Finance]
Medium
Report
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer [Yahoo! Finance]
9/9
12:05 pm
avbp
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
Medium
Report
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
9/6
08:22 am
avbp
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
8/14/2024
04:01 pm
avbp
arrivent biopharma, inc.
IN-LINE
Report
-0.4%
arrivent biopharma, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
02:45 pm
avbp
Form SC 13G ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners XI, L.P.
Low
Report
Form SC 13G ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners XI, L.P.
11/12
09:51 am
avbp
Form SC 13G ArriVent BioPharma, Inc. Filed by: FMR LLC
Low
Report
Form SC 13G ArriVent BioPharma, Inc. Filed by: FMR LLC
11/8
02:22 pm
avbp
Form SC 13G ArriVent BioPharma, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G ArriVent BioPharma, Inc. Filed by: BlackRock, Inc.
10/24
02:03 pm
avbp
Form SC 13G ArriVent BioPharma, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G ArriVent BioPharma, Inc. Filed by: BlackRock, Inc.
10/11
04:03 pm
avbp
Form SC 13G ArriVent BioPharma, Inc. Filed by: Octagon Capital Advisors LP
Low
Report
Form SC 13G ArriVent BioPharma, Inc. Filed by: Octagon Capital Advisors LP
9/23
06:14 pm
avbp
Form 4 ArriVent BioPharma, Inc. For: Sep 19 Filed by: LaChapelle Robin
Medium
Report
Form 4 ArriVent BioPharma, Inc. For: Sep 19 Filed by: LaChapelle Robin
9/9
12:16 pm
avbp
Form 8-K ArriVent BioPharma, Inc. For: Sep 09
Medium
Report
Form 8-K ArriVent BioPharma, Inc. For: Sep 09
8/14
04:17 pm
avbp
Form 10-Q ArriVent BioPharma, Inc. For: Jun 30
Low
Report
Form 10-Q ArriVent BioPharma, Inc. For: Jun 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: